Document is current

Article History

Received: 6 April 2022

Accepted: 9 November 2022

First Online: 18 November 2022

Declarations

:

: This study was approved by the University of Waterloo Research Ethics Board (ORE#41071 and 40700). All methods were performed in accordance with the relevant guidelines and regulations. All survey respondents were provided with an emailed invitation to participate, which included a description of the study purpose and a summary of the survey. The email invited the prospective respondent to contact the study team if they had any questions. It also stated that their voluntary completion of the survey indicated their informed consent (no further consent was sought), that any personal identifiers would be retained by Leger and not shared with the study team, and that their responses would be used in an aggregate analysis for publication.

: Not applicable.

: NMW reports grants from Sanofi Pasteur during the conduct of the study, and personal fees from Sanofi Pasteur outside of the submitted work. JAP has previously provided consulting services to Sanofi Pasteur, outside of the submitted work. SKDH reports grants from Sanofi Pasteur during the conduct of the study, and grants and personal fees from GSK, personal fees from Astra Zeneca, grants from Sanofi and Merck outside of the submitted work. MKA reports grants from Sanofi during the conduct of the study, and grants from Sanofi, GSK, Pfizer and the Canadian Frailty Network, personal fees from Immunovaccine Technologies, Sanofi, Pfizer and Seqirus and grants from the Canadian Institutes of Health Research and the Public Health Agency of Canada, outside of the submitted work.